4-ethyl-5-hydroxymethyl-2-methyl-pyridin-3-ol | 62178-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-ethyl-5-hydroxymethyl-2-methyl-pyridin-3-ol
• 英文别名: 4-Ethyl-5-(hydroxymethyl)-2-methylpyridin-3-ol
• CAS: 62178-38-5
• 化学式: C₉H₁₃NO₂
• mdl: MFCD18803397
• 分子量: 167.208
• InChiKey: AULDANNTPXXHBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Dual antiplatelet/anticoagulant pyridoxine analogs
  申请人：Haque Wasimul

  公开号：US20060094761A1

  公开（公告）日：2006-05-04

  Compounds with antiplatelet aggregation and anticoagulant characteristics for the treatment of cardiovascular, cerebrovascular, and cardiovascular related diseases and symptoms, are described. The methods are directed to administering pharmaceutical compositions comprising aryl sulfonic pyridoxine and/or substituted pyridoxine analogs.

  描述了具有抗血小板聚集和抗凝血特性的化合物，用于治疗心血管、脑血管和与心血管相关的疾病和症状。该方法涉及给药含有芳基磺酸吡ridoxine和/或取代吡ridoxine类似物的药物组合物。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'ANOMALIES DU CYCLE DE L'URÉE ET DE MALADIES HÉPATIQUES
  申请人：RAO M SURYA

  公开号：WO2017090007A1

  公开（公告）日：2017-06-01

  The compositions and compounds of formula I, formula II, formula III which includes a molecular conjugate with ornithine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection administration. Such compositions may be used to the treatment of urea cycle disorders and hepatic diseases or its associated complications.

  公式I、公式II、公式III的组合物和化合物包括与鸟氨酸或其多态体、对映体、立体异构体、溶剂合物和水合物形成的分子共轭物。这些盐可以制成药物组合物。药物组合物可以制成口服、颊粘膜、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射给药的制剂。这些组合物可以用于治疗尿素循环紊乱和肝脏疾病或其相关并发症。
• FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE
  申请人：Milne Jill C.

  公开号：US20130059801A1

  公开（公告）日：2013-03-07

  The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.

  本发明涉及脂肪酸酰胺；包含有效量的脂肪酸酰胺的组合物；以及治疗或预防癌症、代谢性疾病或神经退行性疾病的方法，其中包括给予有效量的脂肪酸酰胺。
• BIODEGRADABLE POLYURETHANES AND USE THEREOF
  申请人：CARNEGIE MELLON UNIVERSITY

  公开号：US20150093821A1

  公开（公告）日：2015-04-02

  A biodegradable and biocompatible polyurethane composition synthesized by reacting isocyanate groups of at least one multifunctional isocyanate compound with at least one bioactive agent having at least one reactive group —X which is a hydroxyl group (—OH) or an amine group (—NH 2 ). The polyurethane composition is biodegradable within a living organism to biocompatible degradation products including the bioactive agent. Preferably, the released bioactive agent affects at least one of biological activity or chemical activity in the host organism. A biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is preferably derived from a diurea diol or a diester diol and is preferably biodegradable into biomolecule degradation products or into biomolecule degradation products and a biocompatible diol. Another biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is derived from a diurethane diol and is biodegradable into biomolecule degradation products.

  一种可生物降解和生物相容的聚氨酯组合物，通过将至少一种多官能异氰酸酯化合物的异氰酸基与至少一种具有至少一个反应性基团-X的生物活性剂反应合成，其中该反应性基团是一个羟基(—OH)或胺基(—NH2)。该聚氨酯组合物在生物体内可生物降解为生物相容的降解产物，包括生物活性剂。最好释放的生物活性剂影响宿主生物体的生物活性或化学活性之一。一种可生物降解的聚氨酯组合物包括硬段和软段。每个硬段最好源自双脲二醇或二酯二醇，并最好可生物降解为生物分子降解产物或生物分子降解产物和生物相容性二醇。另一种可生物降解的聚氨酯组合物包括硬段和软段。每个硬段源自二脲基二醇，并可生物降解为生物分子降解产物。
• Diazepane derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10308653B2

  公开（公告）日：2019-06-04

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本公开提供了式（I）化合物及其药用组合物。已发现式（I）化合物可结合溴基链和/或含溴基链的蛋白质（如溴外末端（BET）蛋白质）。还提供了这些化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基团和/或含溴基团蛋白的活性（如活性增加），治疗和/或预防受试者与溴基团或含溴基团蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、神经系统疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。